title: A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention.
abstract: OBJECTIVE
  Periprocedural myocardial injury (PMI) following percutaneous coronary intervention (PCI) has received great attention due to its significant association with mortality and morbidity. Accordingly, cardioprotection during PCI is one of the important therapeutic concerns. Regarding the potential cardiovascular benefits of pentoxifylline this study was performed to evaluate whether the pretreatment pentoxifylline could reduce PMI in patients who are undergoing elective PCI.
  
  
  METHODS
  A randomized clinical trial on 85 patients undergoing elective PCI was performed. The intervention group (n = 41) received 1200 mg pentoxifylline in divided doses plus the standard treatment before PCI, while the control group (n = 44) received the standard treatment. For assessing myocardial damage during PCI, the levels of CK-MB and troponin-I were measured at baseline, 8, and 24 h after the procedure. Then, patients were followed up for a 1-month period regarding the major adverse cardiac effect.
  
  
  RESULTS
  Comparing with the control group, no significant change of CK-MB at 8 (p = 0.315) and 24 h (p = 0.896) after PCI was documented in pentoxifylline group. Similarly, no significant change was found in troponin-I at 8 (p = 0.141) and 24 h (p = 0.256) after PCI.
  
  
  CONCLUSIONS
  This study could not support the pretreatment with pentoxifylline in the prevention of PMI in patients undergoing elective PCI. However, the trend was toward the potential benefit of pentoxifylline.
authors.affiliation: Cardiovascular Research Center, Shahid Madani Heart Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Naser
authors.initials: N
authors.lastname: Aslanabadi
authors.forename: Hamid Reza
authors.initials: HR
authors.lastname: Shirzadi
authors.forename: Hossein
authors.initials: H
authors.lastname: Asghari-Soufi
authors.forename: Samaneh
authors.initials: S
authors.lastname: Dousti
authors.forename: Samad
authors.initials: S
authors.lastname: Ghaffari
authors.forename: Bahram
authors.initials: B
authors.lastname: Sohrabi
authors.forename: Simin Ozar
authors.initials: SO
authors.lastname: Mashayekhi
authors.forename: Hadi
authors.initials: H
authors.lastname: Hamishehkar
authors.forename: Taher
authors.initials: T
authors.lastname: Entezari-Maleki
mesh_terms: D000368:Aged; D052279:Creatine Kinase, MB Form / Q000097:blood; D017558:Elective Surgical Procedures; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control*; D017202:Myocardial Ischemia / Q000097:blood / Q000601:surgery; D010431:Pentoxifylline / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention; D010865:Pilot Projects; D016037:Single-Blind Method; D019210:Troponin I / Q000097:blood
chemical_list: D019210:Troponin I; D052279:Creatine Kinase, MB Form; D010431:Pentoxifylline